Vaxcyte Inc
PCVX42.920USD
+1.270+3.05%
Close 11/10, 16:00（ET）Quotes delayed by 15 min
5.58BMarket Cap
LossP/E TTM
More Details of Vaxcyte Inc Company
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
Vaxcyte Inc Info
Ticker SymbolPCVX
Company nameVaxcyte Inc
IPO dateJun 12, 2020
CEOMr. Grant E. Pickering
Number of employees414
Security typeOrdinary Share
Fiscal year-endJun 12
Address825 Industrial Road, Ste. 300
CitySAN CARLOS
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94070
Phone16508370111
Websitehttps://vaxcyte.com/
Ticker SymbolPCVX
IPO dateJun 12, 2020
CEOMr. Grant E. Pickering
Company Executives of Vaxcyte Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
658.46K
-2.69%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
75.59K
-9.54%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
27.26K
-20.53%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
12.60K
-28.82%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.67K
+54.06%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
8.67K
+54.06%
Mr. Jacks Lee
Mr. Jacks Lee
Independent Director
Independent Director
3.04K
--
Mr. John P. Furey
Mr. John P. Furey
Independent Director
Independent Director
3.04K
--
Dr. Olivier Brandicourt
Dr. Olivier Brandicourt
Independent Director
Independent Director
1.15K
--
Dr. Heath Lukatch, Ph.D.
Dr. Heath Lukatch, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
658.46K
-2.69%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
75.59K
-9.54%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
27.26K
-20.53%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
12.60K
-28.82%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.67K
+54.06%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
8.67K
+54.06%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Oct 31
Updated: Fri, Oct 31
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
11.22%
The Vanguard Group, Inc.
9.39%
RA Capital Management, LP
9.14%
Fidelity Management & Research Company LLC
7.68%
BlackRock Institutional Trust Company, N.A.
6.91%
Other
55.66%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
11.22%
The Vanguard Group, Inc.
9.39%
RA Capital Management, LP
9.14%
Fidelity Management & Research Company LLC
7.68%
BlackRock Institutional Trust Company, N.A.
6.91%
Other
55.66%
Shareholder Types
Shareholders
Proportion
Investment Advisor
46.66%
Investment Advisor/Hedge Fund
34.10%
Hedge Fund
17.68%
Venture Capital
10.87%
Research Firm
2.24%
Bank and Trust
0.84%
Sovereign Wealth Fund
0.75%
Individual Investor
0.68%
Pension Fund
0.51%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
668
148.53M
114.41%
-14.14M
2025Q2
654
150.97M
116.29%
-1.23M
2025Q1
669
149.26M
115.73%
-5.52M
2024Q4
629
143.44M
111.44%
-3.61M
2024Q3
579
138.80M
114.99%
+5.28M
2024Q2
508
125.57M
113.86%
-5.08M
2024Q1
487
122.06M
113.01%
+8.05M
2023Q4
444
106.09M
111.72%
-6.02M
2023Q3
417
110.70M
121.97%
-7.51M
2023Q2
397
109.13M
122.07%
+11.09M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
14.69M
11.32%
+151.06K
+1.04%
Jun 30, 2025
The Vanguard Group, Inc.
11.97M
9.22%
-48.12K
-0.40%
Jun 30, 2025
RA Capital Management, LP
11.97M
9.22%
-223.16K
-1.83%
Jun 30, 2025
Fidelity Management & Research Company LLC
10.05M
7.74%
-677.06K
-6.31%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
9.05M
6.97%
-85.53K
-0.94%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
6.00M
4.62%
+3.30M
+122.04%
Jun 30, 2025
Wellington Management Company, LLP
4.95M
3.82%
-1.46M
-22.79%
Jun 30, 2025
State Street Investment Management (US)
4.94M
3.81%
+534.55K
+12.13%
Jun 30, 2025
Capital Research Global Investors
4.77M
3.68%
-1.34M
-21.90%
Jun 30, 2025
Paradigm BioCapital Advisors LP
3.37M
2.6%
+1.68M
+98.81%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Harbor Health Care ETF
4.32%
ALPS Medical Breakthroughs ETF
2.71%
SPDR S&P Biotech ETF
1.38%
Virtus LifeSci Biotech Clinical Trials ETF
0.75%
Direxion Daily S&P Biotech Bull 3X Shares
0.73%
ProShares Ultra Nasdaq Biotechnology
0.48%
Invesco Nasdaq Biotechnology ETF
0.47%
iShares Biotechnology ETF
0.43%
JPMorgan Fundamental Data Science Small Core ETF
0.35%
iShares Russell 2000 Value ETF
0.28%
View more
Harbor Health Care ETF
Proportion4.32%
ALPS Medical Breakthroughs ETF
Proportion2.71%
SPDR S&P Biotech ETF
Proportion1.38%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.75%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.73%
ProShares Ultra Nasdaq Biotechnology
Proportion0.48%
Invesco Nasdaq Biotechnology ETF
Proportion0.47%
iShares Biotechnology ETF
Proportion0.43%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.35%
iShares Russell 2000 Value ETF
Proportion0.28%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
